Trial Profile
A Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Ampligen® in Patients With Post-COVID Conditions
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Mar 2024
Price :
$35
*
At a glance
- Drugs Rintatolimod (Primary)
- Indications Cognition disorders; COVID 2019 infections; Fatigue
- Focus Therapeutic Use
- Acronyms AMP-518
- Sponsors AIM ImmunoTech
- 29 Feb 2024 According to an AIM ImmunoTech media release, final data set in Post-COVID Conditions expected in Q2 2024.
- 08 Feb 2024 Results presented in the AIM ImmunoTech Media Release.
- 19 Jan 2024 Status changed from active, no longer recruiting to completed.